Page last updated: 2024-12-05

n-methylpyrrolidone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-methylpyrrolidin-2-one: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-methylpyrrolidin-2-one : A member of the class of pyrrolidine-2-ones that is pyrrolidin-2-one in which the hydrogen attached to the nitrogen is replaced by a methyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID13387
CHEMBL ID12543
CHEBI ID7307
MeSH IDM0116284

Synonyms (218)

Synonym
methyl-2-pyrrolidinone
methyl pyrrolidone
2-pyrrolidinone, methyl-
1-methyl-5-pyrrolidinone
n-methyl-.alpha.-pyrrolidinone
m-pyrol
1-methylazacyclopentan-2-one
nsc-4594
1-methylpyrrolidinone
nsc4594
2-pyrrolidinone, 1-methyl-
n-methyl-2-pyrrolidone
wln: t5nvtj a
n-methylpyrrolidinone
methylpyrrolidone
1-methyl-2-pyrrolidone
n-methyl-.gamma.-butyrolactam
n-methyl-.alpha.-pyrrolidone
n-methyl-alpha-pyrrolidone
n-methyl-alpha-pyrrolidinone
n-methylpyrrolidin-2-one
CHEBI:7307 ,
n-methyl-gamma-butyrolactam
inchi=1/c5h9no/c1-6-4-2-3-5(6)7/h2-4h2,1h
2-pyrrolidone,1-methyl mfc5 h9 n1 o1
1-methylpyrrolidin-2-one
1-methylpyrrolidone
hsdb 5022
einecs 212-828-1
methylpyrrolidone, n-
nsc 4594
ai3-23116
ccris 1633
1-methyl-2-pyrrolidinone
872-50-4
n-methylpyrrolidone
NMP ,
n-methyl-2-pyrrolidinone
1-methyl-2-pyrrolidinone, puriss. p.a., >=99.0% (gc)
1-methyl-2-pyrrolidinone, anhydrous, 99.5%
1-methyl-2-pyrrolidinone, spectrophotometric grade, >=99%
CHEMBL12543 ,
n-methyl-pyrrolidone
n-methyl pyrrolidinone
M0418
AKOS000120930
A842053
NCGC00247902-02
NCGC00247902-01
pharmasolve
methylpyrrolidinone
pyrrolidinone, methyl-
30207-69-3
1-methyl-pyrrolidin-2-one
n-methyl-pyrrolidinone
n-methylpyrolidone
n-methyl pyrrolidone
1-methyl-2-pyrrolidon
n-methyl-pyrrolidin-2-one
n-methyl-2-pyrrolidon
n-methylpyrrolidon
ec 212-828-1
sl 1332
microposit 2001
n 0131
unii-jr9ce63fpm
agsolex 1
m 0418
methylpyrrolidone [nf]
pyrol m
jr9ce63fpm ,
dtxsid6020856 ,
dtxcid60856
tox21_202350
cas-872-50-4
NCGC00259899-01
NCGC00253935-01
tox21_300097
51013-18-4
FT-0672137
bdbm50353587
FT-0608052
AM20110252
methylpyrrolidone [usp-rs]
n-methylpyrrolidone [ep monograph]
methyl pyrrolidone [ii]
n-methylpyrrolidone [mart.]
1-methyl-2-pyrrolidinone [hsdb]
methyl pyrrolidone [inci]
n-methylpyrrolidone [usp-rs]
1-methylpyrrolidone [mi]
3P1D
S6282
2687-44-7
J-504921
n-methyl-2-pyrrolidinon
n-methylpyrrolidine-2one
1-methyl pyrrolidone
n-methyl-2-pyrolidone
n-methylpyrolidinone
1-methylpyrrolidine-2-one
1-methyl -2-pyrrolidinone
n-methy pyrrolidinone
1-methyl-2-pyroldinone
1-methyl-2-pyrollidinone
n-methyl-2-pyrollidone
1-methyl-pyrrolin-2-one
1-methyl-2-pirrolidone
1-methy-2-pyrrolidinone
n-methyl 2-pyrrolidinone
n-methyl -2-pyrrolidinone
1-methyl pyrrolidinone
n-methyl-2-pyrolidinone
n-methyl 2-pyrolidone
1methyl-2-pyrrolidinone
methylpyrrolidin-2-one
1-methyl2-pyrrolidone
1-methyl 2-pyrrolidinone
1 -methyl-2-pyrrolidinone
n-methyl pyrollidone
n-methylpyrolidin-2-one
n-methyl-pyrollidone
1-methyl-2-pyrolidone
methyl-2-pyrrolidone
1-methyl-pyrrolidinone
1-methyl-pyrrolidone
n-methy pyrrolidone
n-methylpyrrolidone-
n-methyl pyrrolidon
n-methyl-pyrrolidin -2-one
n-methy-2-pyrrolidone
n-methylpyrollidinone
1-methylpyrrolid-2-one
1methylpyrrolidinone
n-methylpirrolidone
1methyl-2-pyrrolidone
n-methylpyrro-lidinone
n-methypyrrolidone
n-methylpyrroli-dinone
n-methyl-pyrolidone
n-methyl-2-pyrollidinone
n-methyl-pyrrolidon
n-methylpyrrolidine-2-one
1-methyl-2pyrrolidone
1-methyl-2- pyrrolidinone
n-methylpyrollidin-2-one
n-methyl pirrolidone
n-methlypyrrolidinone
n-methyl-pyrrolid-2-one
1-methyl-pyrrolidin-2one
n-methyl 2-pyrrolidone
1-methylpyrolidinone
1-n-methyl-2-pyrrolidinone
n-methylpyrrolid-2-one
n-methylpyrrolidin-one
1-methyl-2-pyrolidinone
n-methyl pyrolidinone
1 -methyl-2-pyrrolidone
n-methyl- pyrrolidone
n-methyl-pyrolidinone
2-pyrrolidone, 1-methyl-
micropure ultra
n-methylpyrrolidone-(2)
1-methylazacyclopentane-2-one
mfcd00003193
FT-0698122
1-methyl-2-pyrrolidinone, spectrophotometric grade
n-methyl pyrrolidon (peptide grade)
1-methyl-2-pyrrolidinone, hplc grade
J-803017
2,5-dichloro-4,6-dimethyl pyridine-3-carbonitrile
n-methyl-2-pyrrolidinone acs reagent
1-methyl-2-pyrrolidinone, analytical standard
gtpl9520
1-methyl-2-pyrrolidinone-d9
1-methyl-2-pyrrolidinone, biotech. grade, >=99.7%
1-methyl-2-pyrrolidinone, acs reagent, >=99.0%
1-methyl-2-pyrrolidinone, saj first grade, >=98.0%
methylpyrrolidone, united states pharmacopeia (usp) reference standard
1-methyl-2-pyrrolidinone, for hplc, >=99%
1-methyl-2-pyrrolidinone, for metal speciation analysis, >=99.0% (gc)
nmp,sp grade
1-methyl-2-pyrrolidinone, anhydrous
1-methyl-2-pyrrolidinone, biosolv(r)
1-methyl-2-pyrrolidone, reagent, acs
1-methyl-2-pyrrolidinone, electronic/cleanroom grade
D78116
1-methyl-2-pyrrolidinone, for synthesis, 99%
n-methylpyrrolidone, pharmaceutical secondary standard; certified reference material
1-methyl-2-pyrrolidinone, 99.5%
1-methyl-2-pyrrolidinone, p.a., acs reagent, 99%
1-methyl-2-pyrrolidinone, reagentplus(r), 99%
1-methyl-2-pyrrolidinone, vetec(tm) reagent grade, 98%
n-methylpyrrolidone; 1-methylpyrrolidin-2-one
DB12521
FT-0700571
residual solvent class 2 - n-methylpyrrolidone
n-methylpyrrolidione
CS-0017258
1-methyl-2-pyrrolidone (low water content)
M3055
Q33103
STL183295
1-methyl-2- pyrrolidin-2-one
1-methyl-pyrrolidine-2-one
max-1 peptide ,
1-methyl-2-pyrrolidone, anhydrous, water 40ppm max.
26876-92-6
HY-Y1275
methylpyrrolidone (usp-rs)
pyrol-m
n-methyl-2-ketopyrrolidine
n-methylpyrrolidone (ep monograph)
methyl pyrrolidone (ii)
n-methylpyrrolidone (usp-rs)
n-methylpyrrolidone (mart.)
BP-31156
Z104478382

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The discoloration was interpreted as a sign of systemic availability of the test substance, but not as an adverse effect."( Repeated dose toxicity study (28 days) in rats and mice with N-methylpyrrolidone (NMP).
Bower, DB; Deckardt, K; Elliott, GS; Gembardt, C; Hildebrand, B; Kennedy, GL; Malek, DE; Malley, LA; Mellert, W; Murphy, SR; Slone, TW; Wright, GA,
)
0.37
" Thus, oral administration of NMP produced developmental toxicity below maternally toxic levels."( Developmental toxicity of N-methyl-2-pyrrolidone administered orally to rats.
Gallissot, F; Langonné, I; Sabaté, JP; Saillenfait, AM, 2002
)
0.31
" There were no adverse effects on embryo/fetal viability or evidence of teratogenicity at any concentration tested."( Developmental toxicity of N-methyl-2-pyrrolidone in rats following inhalation exposure.
Gallissot, F; Morel, G; Saillenfait, AM, 2003
)
0.32
" In conclusion, NEP administered by gavage is embryotoxic and teratogenic at maternal toxic doses."( Developmental toxic effects of N-ethyl-2-pyrrolidone administered orally to rats.
Gallissot, F; Sabaté, JP; Saillenfait, AM,
)
0.13

Pharmacokinetics

ExcerptReferenceRelevance
" To reduce the uncertainty in rat to human extrapolations, physiologically based pharmacokinetic (PBPK) models were developed to describe the pharmacokinetics of NMP in both species."( Quantitative risk analysis for N-methyl pyrrolidone using physiologically based pharmacokinetic and benchmark dose modeling.
Bader, M; Gargas, ML; Hinderliter, PM; Kirman, CR; Poet, TS; van Thriel, C, 2010
)
0.36
" Modern high-throughput small molecule drug discovery requires rapid screening of the pharmacokinetic parameters of multiple candidate molecules in parallel."( Solvent-based formulations for intravenous mouse pharmacokinetic studies: tolerability and recommended solvent dose limits.
Bowman, T; Dean, B; Messick, K; Sambrone, A; Schweiger, M; Thackaberry, EA; Valle, N; Wang, X; Xie, M, 2014
)
0.4
" Short-term and chronic occupational exposure limit (OEL) values were derived using an updated physiologically based pharmacokinetic (PBPK) model for NMP, along with benchmark dose modeling."( Using physiologically based pharmacokinetic modeling and benchmark dose methods to derive an occupational exposure limit for N-methylpyrrolidone.
Kirman, CR; Parod, RJ; Poet, TS; Rodriguez, CE; Rodwell, DE; Schlosser, PM, 2016
)
0.64

Compound-Compound Interactions

ExcerptReferenceRelevance
"This work aimed to achieve long-lasting delivery of radix ophiopogonis polysaccharide (ROP) by sucrose acetate isobutyrate (SAIB)-based in situ forming systems (ISFSs) alone or combined with mono-PEGylation of ROP."( Delivery of radix ophiopogonis polysaccharide via sucrose acetateisobutyrate-based in situ forming systems alone or combined with itsmono-PEGylation.
Feng, Y; Lin, X; Shen, L; Wang, L; Wu, F; Zheng, X, 2018
)
0.48

Bioavailability

ExcerptReferenceRelevance
" The results of this study suggest that PS could be regarded as a potential corneal enhancer to increase the intraocular bioavailability of AC and TM."( Enhancer effects on in vitro corneal permeation of timolol and acyclovir.
Bucolo, C; Montenegro, L; Puglisi, G, 2003
)
0.32
" The bioavailability after percutaneous exposure was equivalent to 15."( Formulation and evaluation of ethylene-vinyl acetate copolymer matrix patches containing formoterol fumarate.
Kakubari, I; Kawakami, J; Shinkai, N; Takayama, K; Takayama, S; Takayasu, T; Uruno, A; Yamauchi, H, 2006
)
0.33
" The absolute bioavailability of tolterodine was 11."( Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder.
Li, Y; Liu, X; Shi, Y; Sui, C; Sun, F; Wu, Y; Zhou, Y, 2013
)
0.39
"Poor solubility and bioavailability are limiting factors for the clinical application of curcumin."( Development and pharmacokinetic evaluation of a curcumin co-solvent formulation.
Bell, EC; John, MK; Liang, D; Xie, H, 2013
)
0.39
"Recently within the lipid based formulation category, Self-nanoemulsifying drug delivery system (SNEDDS) has received considerable attention in the enhancement of bioavailability of poorly water-soluble drugs."( Toxicity Study of a Self-nanoemulsifying Drug Delivery System Containing N-methyl pyrrolidone.
Agrawal, AG; Gide, PS; Kumar, A, 2015
)
0.42
"In this work, poorly water soluble phytochemical ellagic acid (EA) was micronized to increase its solubility and thereby the bioavailability during antisolvent precipitation process using N-methyl pyrrolidone (NMP) as solvent and deionized water as antisolvent."( Preparation and characterization of micronized ellagic acid using antisolvent precipitation for oral delivery.
Ge, Y; Li, Y; Wu, W; Zhang, Y; Zhao, X; Zhong, C; Zu, Y, 2015
)
0.42
"Evaluation of drug precipitation is important in order to address challenges regarding low and variable bioavailability of poorly water-soluble drugs, to assess potential risk of patient safety with infusion therapy, and to explore injectable in situ suspension-forming drug delivery systems."( UV-vis Imaging of Piroxicam Supersaturation, Precipitation, and Dissolution in a Flow-Through Setup.
Chapman, A; Goodall, DM; Jensen, H; Larsen, SW; Petersen, NJ; Sun, Y; Østergaard, J, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" Increased dosage did not produce a proportional increase in the permeation and maximizing the skin-drug contact did not increase penetration: both factors indicate that absorption from deposited drug films was dissolution rate-limited."( Absorption through human skin of ibuprofen and flurbiprofen; effect of dose variation, deposited drug films, occlusion and the penetration enhancer N-methyl-2-pyrrolidone.
Akhter, SA; Barry, BW, 1985
)
0.27
" Plasma levels of intact NMP were analyzed by HPLC through 6 hr after dosing and suggested a rapid distribution phase followed by a slow elimination phase."( Disposition and metabolism of double-labeled [3H and 14C] N-methyl-2-pyrrolidinone in the rat.
Digenis, GA; Wells, DA,
)
0.13
" NMP did show significant responses with strains TA102 and TA104 that were less than two-fold over background, but no clear dose-response relationships were evident."( Mutagenicity and cytotoxicity of N-methyl-2-pyrrolidinone and 4-(methylamino)butanoic acid in the Salmonella/microsome assay.
Digenis, GA; Thomas, HF; Wells, DA, 1988
)
0.27
"The potential toxicity of N-methylpyrrolidone was evaluated following dietary administration for 13 weeks to male and female beagle dogs at dosage levels of 25, 79 and 250 mg per kg body weight per day."( Subchronic feeding study in beagle dogs of N-methylpyrrolidone.
Becci, PJ; Burnette, LW; Gephart, LA; Johnson, WD; Koschier, FJ, 1983
)
0.83
" Treatment at the high dosage level resulted in fewer live fetuses per dam, an increase in the percentage of resorption sites and skeletal abnormalities."( Teratogenicity study of N-methylpyrrolidone after dermal application to Sprague-Dawley rats.
Becci, PJ; Burnette, LW; Knickerbocker, MJ; Parent, RA; Reagan, EL,
)
0.44
" One-third of the orally dosed NMP was not recovered in urine as either NMP, 5-HNMP, MSI, or 2-HMSI."( Major metabolic pathway for N-methyl-2-pyrrolidone in humans.
Akesson, B; Jönsson, BA, 1997
)
0.3
" The dose-response relationship for NMP and experiments with MTX/NMP-mixtures show that the eluted concentrations of solvent are not toxic and do not influence the effects of MTX."( Cytotoxic effect of methotrexate and its solvent on osteosarcoma cells in vitro.
Decker, S; Nies, B; van Valen, F; Winkelmann, W, 1999
)
0.3
" Benchmark dose modeling was used to better define a point of departure (POD) for fetal/pup body weight changes based on dose-response information from two inhalation studies in rats."( Quantitative risk analysis for N-methyl pyrrolidone using physiologically based pharmacokinetic and benchmark dose modeling.
Bader, M; Gargas, ML; Hinderliter, PM; Kirman, CR; Poet, TS; van Thriel, C, 2010
)
0.36
" Firstly, 1 mg mL(-1) of each drug in 20% 1,8-Cineole in ethanol was used; and secondly, 5 mg mL(-1) AT and 1 mg mL(-1) PR in 20% 1-methyl-2-pyrrolidone in ethanol was examined, dosed every 2 h over a 12-h period and receptor phase samples were analyzed by HPLC."( Delivery of atovaquone and proguanil across sublingual membranes, in vitro.
Heard, CM; Ong, CM; Wallace, E,
)
0.13
" Where possible, data from multiple studies were pooled to increase the predictive power of the dose-response data sets."( Using physiologically based pharmacokinetic modeling and benchmark dose methods to derive an occupational exposure limit for N-methylpyrrolidone.
Kirman, CR; Parod, RJ; Poet, TS; Rodriguez, CE; Rodwell, DE; Schlosser, PM, 2016
)
0.64
"An in situ forming gel is a dosage form which is promised for site-specific therapy such as periodontal pocket of periodontitis treatment."( Designing Solvent Exchange-Induced In Situ Forming Gel from Aqueous Insoluble Polymers as Matrix Base for Periodontitis Treatment.
Phaechamud, T; Srichan, T, 2017
)
0.46
" Further dose-finding studies are required to optimise NMP dosing strategies for therapeutic intervention."( A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma.
Cheah, CY; Davis, J; Galettis, P; Koldej, R; Link, EK; Ludford-Menting, M; Martin, JH; Ritchie, D, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
polar aprotic solventA solvent with a comparatively high relative permittivity (or dielectric constant), greater than ca. 15, and a sizable permanent dipole moment, that cannot donate suitably labile hydrogen atoms to form strong hydrogen bonds.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
N-alkylpyrrolidine
lactamCyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.
pyrrolidin-2-onesA pyrrolidinone in which the oxo group is at position 2 of the pyrrolidine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
N-methylpyrrolidone degradation415

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency28.22490.000714.592883.7951AID1259369
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency50.19180.000657.913322,387.1992AID1259377
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency29.92530.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency50.19180.001530.607315,848.9004AID1224841
farnesoid X nuclear receptorHomo sapiens (human)Potency27.52230.375827.485161.6524AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency63.18780.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency60.34370.000229.305416,493.5996AID743069; AID743075
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency29.21640.000323.4451159.6830AID743066; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency2.37480.000627.21521,122.0200AID743219
Cellular tumor antigen p53Homo sapiens (human)Potency30.60670.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bromodomain-containing protein 4Homo sapiens (human)IC50 (µMol)2,660.00000.00040.40329.0500AID1519869
Cannabinoid receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)34,000.00000.00020.660910.0000AID620197
CREB-binding proteinHomo sapiens (human)IC50 (µMol)2,300.00001.30006.689210.0000AID620198
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (148)

Processvia Protein(s)Taxonomy
regulation of transcription by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
chromatin organizationBromodomain-containing protein 4Homo sapiens (human)
DNA damage responseBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionBromodomain-containing protein 4Homo sapiens (human)
positive regulation of DNA-templated transcriptionBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
regulation of inflammatory responseBromodomain-containing protein 4Homo sapiens (human)
positive regulation of T-helper 17 cell lineage commitmentBromodomain-containing protein 4Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICREB-binding proteinHomo sapiens (human)
response to hypoxiaCREB-binding proteinHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayCREB-binding proteinHomo sapiens (human)
chromatin remodelingCREB-binding proteinHomo sapiens (human)
regulation of DNA-templated transcriptionCREB-binding proteinHomo sapiens (human)
protein acetylationCREB-binding proteinHomo sapiens (human)
signal transductionCREB-binding proteinHomo sapiens (human)
canonical NF-kappaB signal transductionCREB-binding proteinHomo sapiens (human)
regulation of smoothened signaling pathwayCREB-binding proteinHomo sapiens (human)
negative regulation of transcription by RNA polymerase ICREB-binding proteinHomo sapiens (human)
N-terminal peptidyl-lysine acetylationCREB-binding proteinHomo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathwayCREB-binding proteinHomo sapiens (human)
protein destabilizationCREB-binding proteinHomo sapiens (human)
cellular response to nutrient levelsCREB-binding proteinHomo sapiens (human)
cellular response to UVCREB-binding proteinHomo sapiens (human)
homeostatic processCREB-binding proteinHomo sapiens (human)
embryonic digit morphogenesisCREB-binding proteinHomo sapiens (human)
positive regulation of DNA-templated transcriptionCREB-binding proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IICREB-binding proteinHomo sapiens (human)
rhythmic processCREB-binding proteinHomo sapiens (human)
protein-containing complex assemblyCREB-binding proteinHomo sapiens (human)
regulation of cellular response to heatCREB-binding proteinHomo sapiens (human)
positive regulation of protein localization to nucleusCREB-binding proteinHomo sapiens (human)
positive regulation of double-strand break repair via homologous recombinationCREB-binding proteinHomo sapiens (human)
chromatin remodelingBromodomain adjacent to zinc finger domain protein 2BHomo sapiens (human)
regulation of transcription by RNA polymerase IIBromodomain adjacent to zinc finger domain protein 2BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (55)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingBromodomain-containing protein 4Homo sapiens (human)
p53 bindingBromodomain-containing protein 4Homo sapiens (human)
chromatin bindingBromodomain-containing protein 4Homo sapiens (human)
transcription coregulator activityBromodomain-containing protein 4Homo sapiens (human)
transcription coactivator activityBromodomain-containing protein 4Homo sapiens (human)
protein bindingBromodomain-containing protein 4Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityBromodomain-containing protein 4Homo sapiens (human)
enzyme bindingBromodomain-containing protein 4Homo sapiens (human)
lysine-acetylated histone bindingBromodomain-containing protein 4Homo sapiens (human)
RNA polymerase II C-terminal domain bindingBromodomain-containing protein 4Homo sapiens (human)
P-TEFb complex bindingBromodomain-containing protein 4Homo sapiens (human)
histone reader activityBromodomain-containing protein 4Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
transcription coactivator bindingCREB-binding proteinHomo sapiens (human)
p53 bindingCREB-binding proteinHomo sapiens (human)
chromatin bindingCREB-binding proteinHomo sapiens (human)
damaged DNA bindingCREB-binding proteinHomo sapiens (human)
transcription coactivator activityCREB-binding proteinHomo sapiens (human)
transcription corepressor activityCREB-binding proteinHomo sapiens (human)
histone acetyltransferase activityCREB-binding proteinHomo sapiens (human)
protein bindingCREB-binding proteinHomo sapiens (human)
zinc ion bindingCREB-binding proteinHomo sapiens (human)
acetyltransferase activityCREB-binding proteinHomo sapiens (human)
peptide N-acetyltransferase activityCREB-binding proteinHomo sapiens (human)
MRF bindingCREB-binding proteinHomo sapiens (human)
histone H3K18 acetyltransferase activityCREB-binding proteinHomo sapiens (human)
histone H3K27 acetyltransferase activityCREB-binding proteinHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCREB-binding proteinHomo sapiens (human)
peptide-lysine-N-acetyltransferase activityCREB-binding proteinHomo sapiens (human)
peptide lactyltransferase activityCREB-binding proteinHomo sapiens (human)
DNA-binding transcription factor bindingCREB-binding proteinHomo sapiens (human)
chromatin DNA bindingCREB-binding proteinHomo sapiens (human)
DNA bindingBromodomain adjacent to zinc finger domain protein 2BHomo sapiens (human)
protein bindingBromodomain adjacent to zinc finger domain protein 2BHomo sapiens (human)
metal ion bindingBromodomain adjacent to zinc finger domain protein 2BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (21)

Processvia Protein(s)Taxonomy
condensed nuclear chromosomeBromodomain-containing protein 4Homo sapiens (human)
nucleusBromodomain-containing protein 4Homo sapiens (human)
nucleoplasmBromodomain-containing protein 4Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytoplasmCREB-binding proteinHomo sapiens (human)
nucleusCREB-binding proteinHomo sapiens (human)
nucleoplasmCREB-binding proteinHomo sapiens (human)
cytoplasmCREB-binding proteinHomo sapiens (human)
cytosolCREB-binding proteinHomo sapiens (human)
nuclear bodyCREB-binding proteinHomo sapiens (human)
chromatinCREB-binding proteinHomo sapiens (human)
histone acetyltransferase complexCREB-binding proteinHomo sapiens (human)
transcription regulator complexCREB-binding proteinHomo sapiens (human)
nucleusBromodomain adjacent to zinc finger domain protein 2BHomo sapiens (human)
chromatinBromodomain adjacent to zinc finger domain protein 2BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID70688Percentage of benzidine-positive murine erythroleukemia cells on day 6.1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Induction of differentiation of leukemia cells in vitro by N-substituted amides, lactams, and 2-pyridones.
AID646015Binding affinity to His-6 tagged BRD3 expressed in Escherichia coli at 100 uM after 60 mins by fluorescence anisotropic analysis2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery.
AID646017Inhibition of His-6 tagged BRD2-RD12 precoupled with biotinylated tetra-acetylated histone H4 expressed in Escherichia coli assessed as protein-protein interaction at 50 uM after 1 hr by TR-FRET assay2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery.
AID1370514Cytotoxicity against human A549 cells assessed as cell viability at 0.1 uM by MTT assay relative to control2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Identification of novel small-molecule inhibitors of Zika virus infection.
AID1370516Cytotoxicity against human A549 cells assessed as cell viability at 10 uM by MTT assay relative to control2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Identification of novel small-molecule inhibitors of Zika virus infection.
AID1370515Cytotoxicity against human A549 cells assessed as cell viability at 1 uM by MTT assay relative to control2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Identification of novel small-molecule inhibitors of Zika virus infection.
AID70690Cell growth was measured on day 6 after murine erythroleukemia cells were exposed at a cell concentration of 1*10e5 cells/mL.1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Induction of differentiation of leukemia cells in vitro by N-substituted amides, lactams, and 2-pyridones.
AID70689Cell growth was measured on day 3, after murine erythroleukemia cells were exposed at a cell concentration of 1*10e5 cells/mL.1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Induction of differentiation of leukemia cells in vitro by N-substituted amides, lactams, and 2-pyridones.
AID28486Second-order rate constant (M-1 s-1) for the alkaline hydrolysis in water at 30 degrees C2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Acylating agents as enzyme inhibitors and understanding their reactivity for drug design.
AID405575Antitubercular activity against Mycobacterium tuberculosis H37Rv after 2 weeks by agar dilution method2008Journal of natural products, Jun, Volume: 71, Issue:6
Dihydroagarofuranoid sesquiterpenes, a lignan derivative, a benzenoid, and antitubercular constituents from the stem of Microtropis japonica.
AID70691Concentration producing the maximum percentage of benzidine-positive cells after 6-days of continuous exposure in murine leukemia cells.1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Induction of differentiation of leukemia cells in vitro by N-substituted amides, lactams, and 2-pyridones.
AID646018Inhibition of His-6 tagged BRD3-RD12 precoupled with biotinylated tetra-acetylated histone H4 expressed in Escherichia coli assessed as protein-protein interaction at 50 uM after 1 hr by TR-FRET assay2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery.
AID620197Inhibition of BAZ2B2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.
AID646016Binding affinity to His-6 tagged BRD4 expressed in Escherichia coli at 100 uM after 60 mins by fluorescence anisotropic analysis2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery.
AID620198Inhibition of CREBBP2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.
AID646014Binding affinity to His-6 tagged BRD2 expressed in Escherichia coli at 100 uM after 60 mins by fluorescence anisotropic analysis2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery.
AID1519869Inhibition of GST-tagged BRD4 BD1 (49 to 170 residues) (unknown origin) using streptavidin-D2 biotinylated tetra-acetylated histone H4 peptide as substrate after 1.5 hrs by FRET assay2019Bioorganic & medicinal chemistry, 12-15, Volume: 27, Issue:24
Synthesis and elaboration of N-methylpyrrolidone as an acetamide fragment substitute in bromodomain inhibition.
AID646019Inhibition of His-6 tagged BRD4-RD12 precoupled with biotinylated tetra-acetylated histone H4 expressed in Escherichia coli assessed as protein-protein interaction at 50 uM after 1 hr by TR-FRET assay2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery.
AID1370517Cytotoxicity against human A549 cells assessed as cell viability at 100 uM by MTT assay relative to control2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Identification of novel small-molecule inhibitors of Zika virus infection.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.
AID1345665Human bromodomain containing 4 (Bromodomain kinase (BRDK) family)2014Cell reports, May-22, Volume: 7, Issue:4
The drug vehicle and solvent N-methylpyrrolidone is an immunomodulator and antimyeloma compound.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (277)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (3.25)18.7374
1990's27 (9.75)18.2507
2000's88 (31.77)29.6817
2010's129 (46.57)24.3611
2020's24 (8.66)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 83.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index83.38 (24.57)
Research Supply Index5.70 (2.92)
Research Growth Index5.15 (4.65)
Search Engine Demand Index152.79 (26.88)
Search Engine Supply Index2.09 (0.95)

This Compound (83.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (2.40%)5.53%
Reviews3 (1.03%)6.00%
Case Studies5 (1.71%)4.05%
Observational0 (0.00%)0.25%
Other277 (94.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]